Lumos Diagnostics Holdings Limited (ASX:LDX)

Market Cap	110.86M +448.6%
Revenue (ttm)	18.31M -16.7%
Net Income	-13.88M
EPS	-0.02
Shares Out	923.87M
PE Ratio	n/a
Forward PE	0.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,870,138
Average Volume	4,330,658
Open	0.1300
Previous Close	0.1250
Day's Range	0.1200 - 0.1400
52-Week Range	0.0260 - 0.3300
Beta	0.61
RSI	25.37
Earnings Date	Apr 20, 2026

About ASX:LDX

Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LDX

Financial Performance

In fiscal year 2025, ASX:LDX's revenue was $12.40 million, an increase of 11.40% compared to the previous year's $11.13 million. Losses were -$7.18 million, -16.40% less than in 2024.

Financial numbers in USD